School of Chinese Medicine
© 2016 by the authors; licensee MDPI, Basel, Switzerland. Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies whilst they have minimal immunogenicity, high production, low cost and high stability, thus are promising inhibitors to rival antibodies for disease therapy. In this review, we will compare the detailed advantages and disadvantages of antibodies and aptamers in therapeutic applications and summarize recent progress in aptamer selection and modification approaches. We will present therapeutic oligonucleotide aptamers in preclinical studies for skeletal diseases and further discuss oligonucleotide aptamers in different stages of clinical evaluation for various disease therapies including macular degeneration, cancer, inflammation and coagulation to highlight the bright commercial future and potential challenges of therapeutic oligonucleotide aptamers.
International Journal of Molecular Sciences
First Page (page number)
Last Page (page number)
Clinical evaluation, Diseases therapy, Monoclonal antibodies, Oligonucleotide aptamers, Preclinical study
Yu, Yuanyuan, Chao Liang, Quanxia Lv, Defang Li, Xuegong Xu, Baoqin Liu, Aiping Lu, and Ge Zhang. "Molecular selection, modification and development of therapeutic oligonucleotide aptamers." International Journal of Molecular Sciences 3.17 (2016): 1-19.